Avenue Biosciences
Last verified 2026-05-18. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.5Mattributed |
|---|---|
| Latest round | seed, $2.5M, 2024-10-01attributed |
| Founded | 2022 |
| Headquarters | Helsinki, Finland |
| Industry | bio |
| Stage | seed |
| Website | avenuebio.com |
Protein-engineering platform that screens thousands of natural and synthetic signal peptides to boost biologic manufacturing yields. Built for biopharma R&D teams developing therapeutic proteins and biologics. Combines high-throughput chemistry, synthetic biology and ML to remove production bottlenecks in life-saving therapies.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-10-01 | seed | $2.5M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $2.5M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $2.5M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | avenuebio.com, read 2026-05-18 |
| Description | self-reported | avenuebio.com, read 2026-05-18 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.